B. Riley Predicts Increased Earnings for X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – B. Riley lifted their FY2024 EPS estimates for shares of X4 Pharmaceuticals in a report released on Monday, November 18th. B. Riley analyst K. Patel now forecasts that the company will earn ($0.17) per share for the year, up from their previous forecast of ($0.68). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.67) per share. B. Riley also issued estimates for X4 Pharmaceuticals’ FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.16) EPS.

A number of other equities research analysts have also weighed in on XFOR. HC Wainwright decreased their target price on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Stifel Nicolaus reduced their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR opened at $0.37 on Wednesday. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The company has a fifty day moving average of $0.57 and a two-hundred day moving average of $0.74. The firm has a market capitalization of $62.76 million, a price-to-earnings ratio of -4.11 and a beta of 0.39. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 239,436 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $131,689.80. Following the completion of the sale, the chief executive officer now owns 1,057,713 shares of the company’s stock, valued at $581,742.15. This trade represents a 18.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Mary Dibiase sold 67,695 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the completion of the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at $257,674.20. This trade represents a 13.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 580,800 shares of company stock worth $321,447. Insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP acquired a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth $340,000. K2 Principal Fund L.P. purchased a new stake in X4 Pharmaceuticals during the second quarter valued at about $284,000. AQR Capital Management LLC increased its position in shares of X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after acquiring an additional 388,115 shares in the last quarter. State Street Corp raised its holdings in shares of X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after buying an additional 189,105 shares during the period. Finally, Barclays PLC boosted its position in X4 Pharmaceuticals by 196.0% in the 3rd quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after buying an additional 183,861 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.